Vancomycin Use in Children and Neonates across Three Decades: A Bibliometric Analysis of the Top-Cited Articles
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Scientific Journals
3.2. Top-Cited Articles
4. Discussion
5. Conclusions and Future Perspectives
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Rybak, M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 2006, 42 (Suppl. S1), S35–S39. [Google Scholar] [CrossRef] [PubMed]
- Butterfield, J.M.; Patel, N.; Pai, M.P.; Rosano, T.G.; Drusano, G.L.; Lodise, T.P. Refining vancomycin protein binding estimates: Identification of clinical factors that influence protein binding. Antimicrob. Agents Chemother. 2011, 55, 4277–4282. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gardete, S.; Tomasz, A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J. Clin. Invest. 2014, 124, 2836–2840. [Google Scholar] [CrossRef] [PubMed]
- Center, K.J.; Reboli, A.C.; Hubler, R.; Rodgers, G.L.; Long, S.S. Decreased Vancomycin Susceptibility of Coagulase-Negative Staphylococci in a Neonatal Intensive Care Unit: Evidence of Spread of Staphylococcus warneri. J. Clin. Microbiol. 2003, 41, 4660–4665. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McGuinness, W.A.; Malachowa, N.; DeLeo, F.R. Vancomycin Resistance in Staphylococcus Aureus. Yale J. Biol. Med. 2017, 90, 269–281. [Google Scholar] [PubMed]
- Le, J.; Nguyen, T.; Law, A.; Hodding, J. Adverse Drug Reactions among Children over a 10-Year Period. Pediatrics 2006, 118, 555–562. [Google Scholar] [CrossRef]
- Polk, R.E. Anaphylactoid reactions to glycopeptide antibiotics. J. Antimicrob. Chemother. 1991, 27 (Suppl. B), 17–29. [Google Scholar] [CrossRef]
- Wilson, A. Comparative safety of teicoplanin and vancomycin. Int. J. Antimicrob. Agents 1998, 10, 143–152. [Google Scholar] [CrossRef]
- McMullan, B.J.; Bowen, A.; Blyth, C.; van Hal, S.; Korman, T.; Buttery, J.; Voss, L.; Roberts, S.; Cooper, C.; Tong, S.; et al. Epidemiology and Mortality of Staphylococcus aureus Bacteremia in Australian and New Zealand Children. JAMA Pediatr. 2016, 170, 979–986. [Google Scholar] [CrossRef] [PubMed]
- Carey, A.J.; Saiman, L.; Polin, R.A. Hospital-Acquired Infections in the NICU: Epidemiology for the New Millennium. Clin. Perinatol. 2008, 35, 223–249. [Google Scholar] [CrossRef] [PubMed]
- Nelson, M.U.; Gallagher, P.G. Methicillin-Resistant Staphylococcus aureus in the Neonatal Intensive Care Unit. Semin. Perinatol. 2012, 36, 424–430. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kronman, M.P.; Zaoutis, T.E.; Haynes, K.; Feng, R.; Coffin, S.E. Antibiotic Exposure and IBD Development among Children: A Population-Based Cohort Study. Pediatrics 2012, 130, e794–e803. [Google Scholar] [CrossRef] [Green Version]
- Grimsley, C.; Thomson, A.H. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch. Dis. Child. Fetal Neonatal Ed. 1999, 81, F221–F227. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Singh, R.; Ray, P.; Das, A.; Sharma, M. Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms. J. Antimicrob. Chemother. 2010, 65, 1955–1958. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Blaskovich, M.A.T.; Hansford, K.A.; Butler, M.S.; Jia, Z.; Mark, A.E.; Cooper, M.A. Developments in Glycopeptide Antibiotics. ACS Infect. Dis. 2018, 4, 715–735. [Google Scholar] [CrossRef] [Green Version]
- Boyce, J.M.; Cookson, B.; Christiansen, K.; Hori, S.; Vuopio-Varkila, J.; Kocagöz, S.; Öztop, A.Y.; Vandenbroucke-Grauls, C.M.; Harbarth, S.; Pittet, D. Meticillin-resistant Staphylococcus aureus. Lancet Infect. Dis. 2005, 5, 653–663. [Google Scholar] [CrossRef]
- Deresinski, S. Counterpoint: Vancomycin and Staphylococcus aureus--An Antibiotic Enters Obsolescence. Clin. Infect. Dis. 2007, 44, 1543–1548. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Herigon, J.; Hersh, A.L.; Gerber, J.S.; Zaoutis, T.E.; Newland, J.G. Antibiotic Management of Staphylococcus aureus Infections in US Children’s Hospitals, 1999–2008. Pediatrics 2010, 125, e1294–e1300. [Google Scholar] [CrossRef]
- Jarvis, W.R. Epidemiology, Appropriateness, and Cost of Vancomycin Use. Clin. Infect. Dis. 1998, 26, 1200–1203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jones, R.N. Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant Strains. Clin. Infect. Dis. 2006, 42 (Suppl. 1), S13–S24. [Google Scholar] [CrossRef]
- Stevens, D.L. The Role of Vancomycin in the Treatment Paradigm. Clin. Infect. Dis. 2006, 42 (Suppl. 1), S51–S57. [Google Scholar] [CrossRef] [PubMed]
- Moellering, J.R.C. Vancomycin: A 50-Year Reassessment. Clin. Infect. Dis. 2006, 42 (Suppl. 1), S3–S4. [Google Scholar] [CrossRef] [PubMed]
- Mohr, J.F.; Murray, B.E. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2007, 44, 1536–1542. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Patel, N.; Pai, M.P.; Rodvold, K.A.; Lomaestro, B.; Drusano, G.L.; Lodise, T.P. Vancomycin: We Can’t Get There From Here. Clin. Infect. Dis. 2011, 52, 969–974. [Google Scholar] [CrossRef] [Green Version]
- Rubin, L.G.; Sánchez, P.J.; Siegel, J.; Levine, G.; Saiman, L.; Jarvis, W.R. Evaluation and treatment of neonates with suspected late-onset sepsis: A survey of neonatologists’ practices. Pediatrics 2002, 110, e42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Levine, D.P. Vancomycin: A History. Clin. Infect. Dis. 2006, 42 (Suppl. 1), S5–S12. [Google Scholar] [CrossRef] [PubMed]
- Tice, A.D.; Rehm, S.J.; Dalovisio, J.R.; Bradley, J.S.; Martinelli, L.P.; Graham, D.R.; Gainer, R.B.; Kunkel, M.J.; Yancey, R.W.; Williams, D.N. Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy. Clin. Infect. Dis. 2004, 38, 1651–1671. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Courvalin, P. Vancomycin Resistance in Gram-Positive Cocci. Clin. Infect. Dis. 2006, 42 (Suppl. 1), S25–S34. [Google Scholar] [CrossRef]
- Falagas, M.; Makris, G.; Dimopoulos, G.; Matthaiou, D. Heteroresistance: A concern of increasing clinical significance? Clin. Microbiol. Infect. 2008, 14, 101–104. [Google Scholar] [CrossRef] [Green Version]
- Stryjewski, M.; Corey, G.R. Methicillin-Resistant Staphylococcus aureus: An Evolving Pathogen. Clin. Infect. Dis. 2014, 58 (Suppl. 1), S10–S19. [Google Scholar] [CrossRef] [Green Version]
- Healy, C.M.; Hulten, K.; Palazzi, D.L.; Campbell, J.R.; Baker, C.J. Emergence of New Strains of Methicillin-Resistant Staphylococcus aureus in a Neonatal Intensive Care Unit. Clin. Infect. Dis. 2004, 39, 1460–1466. [Google Scholar] [CrossRef]
- Cosgrove, S.E. The Relationship between Antimicrobial Resistance and Patient Outcomes: Mortality, Length of Hospital Stay, and Health Care Costs. Clin. Infect. Dis. 2006, 42 (Suppl. 2), S82–S89. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gold, H.S. Vancomycin-Resistant Enterococci: Mechanisms and Clinical Observations. Clin. Infect. Dis. 2001, 33, 210–219. [Google Scholar] [CrossRef]
- Weinstein, R.A.; Fridkin, S.K. Vancomycin-Intermediate and -Resistant Staphylococcus aureus: What the Infectious Disease Specialist Needs to Know. Clin. Infect. Dis. 2001, 32, 108–115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arthur, M.; Reynolds, P.; Depardieu, F.; Evers, S.; Dutka-Malen, S.; Quintiliani, R.; Courvalin, P. Mechanisms of glycopeptide resistance in enterococci. J. Infect. 1996, 32, 11–16. [Google Scholar] [CrossRef]
- Bizzarro, M.J.; Gallagher, P.G. Antibiotic-Resistant Organisms in the Neonatal Intensive Care Unit. Semin. Perinatol. 2007, 31, 26–32. [Google Scholar] [CrossRef] [PubMed]
- Dietrich, D.W.; Auld, D.B.; Mermel, L.A. Community-Acquired Methicillin-Resistant Staphylococcus aureus in Southern New England Children. Pediatrics 2004, 113, e347–e352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Donskey, C.J. The Role of the Intestinal Tract as a Reservoir and Source for Transmission of Nosocomial Pathogens. Clin. Infect. Dis. 2004, 39, 219–226. [Google Scholar] [CrossRef] [Green Version]
- French, G.L. Enterococci and Vancomycin Resistance. Clin. Infect. Dis. 1998, 27 (Suppl. 1), S75–S83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalima, P.; Masterton, R.; Roddie, P.; Thomas, A. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J. Infect. 1996, 32, 165–167. [Google Scholar] [CrossRef]
- Kollef, M.H. Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections. Clin. Infect. Dis. 2007, 45, S191–S195. [Google Scholar] [CrossRef] [PubMed]
- Leclercq, R.; Dutka-Malen, S.; Brisson-Noël, A.; Molinas, C.; Derlot, E.; Arthur, M.; Duval, J.; Courvalin, P. Resistance of Enterococci to Aminoglycosides and Glycopeptides. Clin. Infect. Dis. 1992, 15, 495–501. [Google Scholar] [CrossRef] [PubMed]
- Leclercq, R.; Courvalin, P. Resistance to Glycopeptides in Enterococci. Clin. Infect. Dis. 1997, 24, 545–554, quiz 555–556. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin. Infect. Dis. 2011, 52, e18–e55. [Google Scholar] [CrossRef] [Green Version]
- Moellering, J.R.C. Vancomycin-Resistant Enterococci. Clin. Infect. Dis. 1998, 26, 1196–1199. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Molton, J.; Tambyah, P.A.; Ang, B.S.P.; Ling, M.L.; Fisher, D.A. The Global Spread of Healthcare-Associated Multidrug-Resistant Bacteria: A Perspective From Asia. Clin. Infect. Dis. 2013, 56, 1310–1318. [Google Scholar] [CrossRef]
- Rehm, S.J.; Tice, A. Staphylococcus aureus: Methicillin-SusceptibleS. aureusto Methicillin-ResistantS. aureusand Vancomycin-Resistant S. aureus. Clin. Infect. Dis. 2010, 51 (Suppl. 2), S176–S182. [Google Scholar] [CrossRef] [Green Version]
- Rodvold, K.A.; McConeghy, K.W. Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future. Clin. Infect. Dis. 2014, 58 (Suppl. 1), S20–S27. [Google Scholar] [CrossRef]
- Rubinstein, E.; Kollef, M.H.; Nathwani, D. Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus. Clin. Infect. Dis. 2008, 46 (Suppl. 5), S378–S385. [Google Scholar] [CrossRef] [Green Version]
- Stryjewski, M.E.; Chambers, H.F. Skin and Soft-Tissue Infections Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus. Clin. Infect. Dis. 2008, 46 (Suppl. 5), S368–S377. [Google Scholar] [CrossRef] [Green Version]
- Tacconelli, E.; Carrara, E.; Savoldi, A.; Harbarth, S.; Mendelson, M.; Monnet, D.L.; Pulcini, C.; Kahlmeter, G.; Kluytmans, J.; Carmeli, Y.; et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018, 18, 318–327. [Google Scholar] [CrossRef]
- Talbot, G.H.; Bradley, J.; Edwards, J.J.E.; Gilbert, D.; Scheld, M.; Bartlett, J.G. Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 2006, 42, 657–668. [Google Scholar] [CrossRef] [Green Version]
- Zaoutis, T.E.; Prasad, P.A.; Localio, A.R.; Coffin, S.E.; Bell, L.M.; Walsh, T.J.; Gross, R. Risk Factors and Predictors for Candidemia in Pediatric Intensive Care Unit Patients: Implications for Prevention. Clin. Infect. Dis. 2010, 51, e38–e45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zembower, T.R.; A Noskin, G.; Postelnick, M.J.; Nguyen, C.; Peterson, L.R. The utility of aminoglycosides in an era of emerging drug resistance. Int. J. Antimicrob. Agents 1998, 10, 95–105. [Google Scholar] [CrossRef]
- de Hoog, M.; Mouton, J.W.; Anker, J.N.V.D. New dosing strategies for antibacterial agents in the neonate. Semin. Fetal Neonatal Med. 2005, 10, 185–194. [Google Scholar] [CrossRef]
- Downes, K.J.; Hahn, A.; Wiles, J.; Courter, J.D.; Vinks, A.A. Dose optimisation of antibiotics in children: Application of pharmacokinetics/pharmacodynamics in paediatrics. Int. J. Antimicrob. Agents 2014, 43, 223–230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harskamp-van Ginkel, M.W.; Hill, K.D.; Becker, K.C.; Testoni, D.; Cohen-Wolkowiez, M.; Gonzalez, D.; Barrett, J.S.; Benjamin, D.J.; Siegel, D.A.; Banks, P.; et al. Drug Dosing and Pharmacokinetics in Children With Obesity A Systematic Review. JAMA Pediatr. 2015, 169, 678–685. [Google Scholar] [CrossRef]
- Jacqz-Aigrain, E.; Zhao, W.; Sharland, M.; van den Anker, J.N. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin. Fetal Neonatal Med. 2013, 18, 28–34. [Google Scholar] [CrossRef]
- Leroux, S.; Zhao, W.; Bétrémieux, P.; Pladys, P.; Saliba, E.; Jacqz-Aigrain, E. Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: A French national survey. Arch. Dis. Child. 2015, 100, 394–398. [Google Scholar] [CrossRef] [Green Version]
- Moellering, J.R.C. Editorial: Monitoring Serum Vancomycin Levels: Climbing the Mountain Because It Is There? Clin. Infect. Dis. 1994, 18, 544–546. [Google Scholar] [CrossRef]
- Oudin, C.; Vialet, R.; Boulamery, A.; Martin, C.; Simon, N. Vancomycin prescription in neonates and young infants: Toward a simplified dosage. Arch. Dis. Child.-Fetal Neonatal Ed. 2011, 96, F365–F370. [Google Scholar] [CrossRef] [PubMed]
- Plan, O.; Cambonie, G.; Barbotte, E.; Meyer, P.; Devine, C.; Milesi, C.; Pidoux, O.; Badr, M.; Picaud, J.C. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: A new dosage schedule. Arch. Dis. Child. Fetal Neonatal Ed. 2008, 93, F418–F421. [Google Scholar] [CrossRef] [PubMed]
- Rubin, L.G.; Papsin, B. Committee on Infectious Diseases and Section on Otolaryngology-Head and Neck Surgery Cochlear Implants in Children: Surgical Site Infections and Prevention and Treatment of Acute Otitis Media and Meningitis. Pediatrics 2010, 126, 381–391. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tobin, C.M.; Darville, J.M.; Thomson, A.H.; Sweeney, G.; Wilson, J.F.; MacGowan, A.P.; White, L.O. Vancomycin therapeutic drug monitoring: Is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J. Antimicrob. Chemother. 2002, 50, 713–718. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, W.; Lopez, E.; Biran, V.; Durrmeyer, X.; Fakhoury, M.; Jacqz-Aigrain, E. Vancomycin continuous infusion in neonates: Dosing optimisation and therapeutic drug monitoring. Arch. Dis. Child. 2013, 98, 449–453. [Google Scholar] [CrossRef] [PubMed]
- Berg, A.L. Newborn Hearing Screening in the NICU: Profile of Failed Auditory Brainstem Response/Passed Otoacoustic Emission. Pediatrics 2005, 116, 933–938. [Google Scholar] [CrossRef]
- de Hoog, M.; van Zanten, B.A.; Hop, W.C.; Overbosch, E.; Weisglas-Kuperus, N.; Anker, J.N.V.D. Newborn hearing screening: Tobramycin and vancomycin are not risk factors for hearing loss. J. Pediatr. 2003, 142, 41–46. [Google Scholar] [CrossRef]
- Downes, K.J.; Cowden, C.; Laskin, B.L.; Huang, Y.-S.; Gong, W.; Bryan, M.; Fisher, B.T.; Goldstein, S.L.; Zaoutis, T.E. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. JAMA Pediatr. 2017, 171, e173219. [Google Scholar] [CrossRef]
- Hammond, D.; Smith, M.N.; Li, C.; Hayes, S.M.; Lusardi, K.; Bookstaver, P.B. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin. Infect. Dis. 2016, 64, 666–674. [Google Scholar] [CrossRef]
- McKamy, S.; Hernandez, E.; Jahng, M.; Moriwaki, T.; Deveikis, A.L.J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J. Pediatr. 2011, 158, 422–426. [Google Scholar] [CrossRef]
- Narendra, A.; White, M.P.; A Rolton, H.; I Alloub, Z.; Wilkinson, G.; McColl, J.; Beattie, J. Nephrocalcinosis in preterm babies. Arch. Dis. Child.-Fetal Neonatal Ed. 2001, 85, F207–F213. [Google Scholar] [CrossRef] [PubMed]
- Rhodin, M.M.; Anderson, B.J.; Peters, A.M.; Coulthard, M.G.; Wilkins, B.; Cole, M.; Chatelut, E.; Grubb, A.; Veal, G.; Keir, M.J.; et al. Human renal function maturation: A quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 2009, 24, 67–76. [Google Scholar] [CrossRef] [PubMed]
- Stojanović, V.; Barisic, N.; Milanović, B.; Doronjski, A. Acute kidney injury in preterm infants admitted to a neonatal intensive care unit. Pediatr. Nephrol. 2014, 29, 2213–2220. [Google Scholar] [CrossRef]
- Boucher, H.; Miller, L.G.; Razonable, R.R. Serious Infections Caused by Methicillin-Resistant Staphylococcus aureus. Clin. Infect. Dis. 2010, 51, S183–S197. [Google Scholar] [CrossRef] [Green Version]
- Cometta, A.; Kern, W.V.; De Bock, R.; Paesmans, M.; Vandenbergh, M.; Crokaert, F.; Engelhard, D.; Marchetti, O.; Akan, H.; Skoutelis, A.; et al. Vancomycin versus Placebo for Treating Persistent Fever in Patients with Neutropenic Cancer Receiving Piperacillin-Tazobactam Monotherapy. Clin. Infect. Dis. 2003, 37, 382–389. [Google Scholar] [CrossRef]
- Creel, A.M.; Durham, S.H.; Benner, K.W.; Alten, J.A.; Winkler, M.K. Severe invasive community-associated methicillin-resistant Staphylococcus aureus infections in previously healthy children *. Pediatr. Crit. Care Med. 2009, 10, 323–327. [Google Scholar] [CrossRef]
- Darouiche, R.O.; Dhir, A.; Miller, A.J.; Landon, G.C.; Raad, I.I.; Musher, D.M. Vancomycin Penetration Into Biofilm Covering Infected Prostheses And Effect On Bacteria. J. Infect. Dis. 1994, 170, 720–723. [Google Scholar] [CrossRef]
- Davies, Y.K.; Cox, K.M.; A Abdullah, B.; Safta, A.; Terry, A.B.; Cox, K.L. Long-term Treatment of Primary Sclerosing Cholangitis in Children With Oral Vancomycin: An Immunomodulating Antibiotic. J. Pediatr. Gastroenterol. Nutr. 2008, 47, 61–67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Denniston, S.; I Riordan, F.A. Staphylococcus aureus bacteraemia in children and neonates: A 10 year retrospective review. J. Infect. 2006, 53, 387–393. [Google Scholar] [CrossRef]
- Dubnov-Raz, G.; Scheuerman, O.; Chodick, G.; Finkelstein, Y.; Samra, Z.; Garty, B.Z. Invasive Kingella kingae Infections in Children: Clinical and Laboratory Characteristics. Pediatrics 2008, 122, 1305–1309. [Google Scholar] [CrossRef] [PubMed]
- Falagas, M.E.; Siempos, I.I.; Vardakas, K.Z. Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: Meta-analysis of randomised controlled trials. Lancet Infect. Dis. 2008, 8, 53–66. [Google Scholar] [CrossRef]
- Garland, J.S.; Alex, C.P.; Henrickson, K.J.; McAuliffe, T.L.; Maki, D.G. A Vancomycin-Heparin Lock Solution for Prevention of Nosocomial Bloodstream Infection in Critically Ill Neonates With Peripherally Inserted Central Venous Catheters: A Prospective, Randomized Trial. Pediatrics 2005, 116, e198–e205. [Google Scholar] [CrossRef] [Green Version]
- Hiramatsu, K.; Hanaki, H.; Ino, T.; Yabuta, K.; Oguri, T.; Tenover, F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 1997, 40, 135–136. [Google Scholar] [CrossRef]
- Kacica, M.A.; Horgan, M.J.; Ochoa, L.; Sandler, R.; Lepow, M.L.; Venezia, R.A. Prevention of gram-positive sepsis in neonates weighing less than 1500 grams. J. Pediatr. 1994, 125, 253–258. [Google Scholar] [CrossRef]
- Karlowicz, M.G.; Buescher, E.S.; Surka, A.E. Fulminant Late-Onset Sepsis in a Neonatal Intensive Care Unit, 1988-1997, and the Impact of Avoiding Empiric Vancomycin Therapy. Pediatrics 2000, 106, 1387–1390. [Google Scholar] [CrossRef] [PubMed]
- Makhoul, I.R.; Kassis, I.; Smolkin, T.; Tamir, A.; Sujov, P. Review of 49 neonates with acquired fungal sepsis: Further characterization. Pediatrics 2001, 107, 61–66. [Google Scholar] [CrossRef] [PubMed]
- Nichols, R.L. Optimal treatment of complicated skin and skin structure infections. J. Antimicrob. Chemother. 1999, 44, 19–23. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pammi, M.; Liang, R.; Hicks, J.M.; Barrish, J.; Versalovic, J. Farnesol Decreases Biofilms of Staphylococcus epidermidis and Exhibits Synergy With Nafcillin and Vancomycin. Pediatr. Res. 2011, 70, 578–583. [Google Scholar] [CrossRef] [Green Version]
- Rackoff, W.R.; Weiman, M.; Jakobowski, D.; Hirschl, R.; Stallings, V.; Bilodeau, J.; Danz, P.; Bell, L.; Lange, B. A randomized, controlled trial of the efficacy ofheparin and vancomycin solution in preventing central venous catheter infections in children. J. Pediatr. 1995, 127, 147–151. [Google Scholar] [CrossRef]
- Safdar, N.; Maki, D.G. Use of Vancomycin-Containing Lock or Flush Solutions for Prevention of Bloodstream Infection Associated with Central Venous Access Devices: A Meta-Analysis of Prospective, Randomized Trials. Clin. Infect. Dis. 2006, 43, 474–484. [Google Scholar] [CrossRef] [Green Version]
- Salzman, M.B.; Isenberg, H.D.; Shapiro, J.F.; Lipsitz, P.J.; Rubin, L.G. A Prospective Study of the Catheter Hub as the Portal of Entry for Microorganisms Causing Catheter-Related Sepsis in Neonates. J. Infect. Dis. 1993, 167, 487–490. [Google Scholar] [CrossRef]
- Sejvar, J.J.; Tenover, F.C.; Stephens, D.S. Management of anthrax meningitis. Lancet Infect. Dis. 2005, 5, 287–295. [Google Scholar] [CrossRef]
- Seltz, L.B.; Smith, J.; Durairaj, V.D.; Enzenauer, R.; Todd, J. Microbiology and Antibiotic Management of Orbital Cellulitis. Pediatrics 2011, 127, e566–e572. [Google Scholar] [CrossRef]
- Shane, A.L.; Stoll, B.J. Neonatal sepsis: Progress towards improved outcomes. J. Infect. 2014, 68, S24–S32. [Google Scholar] [CrossRef]
- Siu, Y.K.; Ng, P.C.; Fung, S.C.K.; Lee, C.H.; Wong, M.Y.; Fok, T.F.; So, K.W.; Cheung, K.L.; Wong, W.; Cheng, A.F.B. Double blind, randomised, placebo controlled study of oral vancomycin in prevention of necrotising enterocolitis in preterm, very low birthweight infants. Arch. Dis. Child.-Fetal Neonatal Ed. 1998, 79, F105–F109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Spafford, P.S.; Sinkin, R.A.; Cox, C.; Reubens, L.; Powell, K.R. Prevention of central venous catheter-related coagulase-negative staphylococcal sepsis in neonates. J. Pediatr. 1994, 125, 259–263. [Google Scholar] [CrossRef]
- Tunkel, A.R.; Hasbun, R.; Bhimraj, A.; Byers, K.; Kaplan, S.L.; Scheld, W.M.; van de Beek, D.; Bleck, T.P.; Garton, H.J.; Zunt, J.R. 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis *. Clin. Infect. Dis. 2017, 64, e34–e65. [Google Scholar] [CrossRef] [PubMed]
- Van den Hoogen, A.; Gerards, L.J.; Verboon-Maciolek, M.A.; Fleer, A.; Krediet, T.G. Long-Term Trends in the Epidemiology of Neonatal Sepsis and Antibiotic Susceptibility of Causative Agents. Neonatology 2010, 97, 22–28. [Google Scholar] [CrossRef] [PubMed]
- Van Hal, S.J.; Fowler, J.V.G. Is It Time to Replace Vancomycin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infections? Clin. Infect. Dis. 2013, 56, 1779–1788. [Google Scholar] [CrossRef] [Green Version]
- Van Vliet, M.J.; Tissing, W.J.E.; Dun, C.A.J.; Meessen, N.E.L.; Kamps, W.A.; de Bont, E.S.J.M.; Harmsen, H.J.M. Chemotherapy Treatment in Pediatric Patients with Acute Myeloid Leukemia Receiving Antimicrobial Prophylaxis Leads to a Relative Increase of Colonization with Potentially Pathogenic Bacteria in the Gut. Clin. Infect. Dis. 2009, 49, 262–270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weisman, L.E.; Thackray, H.M.; Steinhorn, R.H.; Walsh, W.F.; Lassiter, H.A.; Dhanireddy, R.; Brozanski, B.S.; Palmer, K.G.H.; Trautman, M.S.; Escobedo, M.; et al. A Randomized Study of a Monoclonal Antibody (Pagibaximab) to Prevent Staphylococcal Sepsis. Pediatrics 2011, 128, 271–279. [Google Scholar] [CrossRef]
- Wisplinghoff, H.; Bischoff, T.; Tallent, S.M.; Seifert, H.; Wenzel, R.P.; Edmond, M.B. Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clin. Infect. Dis. 2004, 39, 309–317. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, K.S.; Lin, T.Y.; Huang, Y.C.; Hsia, S.H.; Yang, P.H.; Chu, S.M. Clinical and radiographic spectrum of septic pulmonary embolism. Arch. Dis. Child. 2002, 87, 312–315. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- El Feghaly, R.E.; Stauber, J.L.; Tarr, P.I.; Haslam, D.B. Intestinal Inflammatory Biomarkers and Outcome in Pediatric Clostridium difficile Infections. J. Pediatr. 2013, 163, 1697–1704.e2. [Google Scholar] [CrossRef] [Green Version]
- Bartlett, J.G. Clostridium difficile: History of Its Role as an Enteric Pathogen and the Current State of Knowledge About the Organism. Clin. Infect. Dis. 1994, 18, S265–S272. [Google Scholar] [CrossRef]
- Cohen, M.B. Clostridium difficile Infections: Emerging Epidemiology and New Treatments. J. Pediatr. Gastroenterol. Nutr. 2009, 2, S63–S65. [Google Scholar] [CrossRef] [PubMed]
- Debast, S.B.; Bauer, M.P.; Kuijper, E.J. European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect 2014, 20, 1–26. [Google Scholar] [CrossRef] [Green Version]
- McDonald, L.C.; Gerding, D.N.; Johnson, S.; Bakken, J.S.; Carroll, K.C.; Coffin, S.E.; Dubberke, E.R.; Garey, K.W.; Gould, C.V.; Kelly, C.; et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018, 66, e1–e48. [Google Scholar] [CrossRef] [PubMed]
- Mezoff, E.; Mann, E.A.; Hart, K.W.; Lindsell, C.J.; Cohen, M.B. Clostridium difficile Infection and Treatment in the Pediatric Inflammatory Bowel Disease Population. J. Pediatr. Gastroenterol. Nutr. 2011, 52, 437–441. [Google Scholar] [CrossRef] [Green Version]
- Pépin, J.; Routhier, S.; Gagnon, S.; Brazeau, I. Management and Outcomes of a First Recurrence of Clostridium difficile-Associated Disease in Quebec, Canada. Clin. Infect. Dis. 2006, 42, 758–764. [Google Scholar] [CrossRef]
- Russell, G.; Kaplan, J.; Ferraro, M.; Michelow, I.C. Fecal Bacteriotherapy for Relapsing Clostridium difficile Infection in a Child: A Proposed Treatment Protocol. Pediatrics 2010, 126, e239–e242. [Google Scholar] [CrossRef]
- Schutze, G.E.; Willoughby, R.E.; Committee on Infectious Diseases; American Academy of Pediatrics. Clostridium difficile Infection in Infants and Children. Pediatrics 2013, 131, 196–200. [Google Scholar] [CrossRef] [Green Version]
- Youngster, I.; Sauk, J.; Pindar, C.; Wilson, R.G.; Kaplan, J.L.; Smith, M.B.; Alm, E.J.; Gevers, D.; Russell, G.H.; Hohmann, E.L. Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study. Clin. Infect. Dis. 2014, 58, 1515–1522. [Google Scholar] [CrossRef]
- Blinova, E.; Lau, E.; Bitnun, A.; Cox, P.; Schwartz, S.; Atenafu, E.; Yau, Y.; Streitenberger, L.; Parshuram, C.S.; Marshall, J.; et al. Point Prevalence Survey of Antimicrobial Utilization in the Cardiac and Pediatric Critical Care Unit. Pediatr. Crit. Care Med. 2013, 14, e280–e288. [Google Scholar] [CrossRef] [PubMed]
- Clark, R.H.; Bloom, B.T.; Spitzer, A.R.; Gerstmann, D.R. Reported Medication Use in the Neonatal Intensive Care Unit: Data From a Large National Data Set. Pediatrics 2006, 117, 1979–1987. [Google Scholar] [CrossRef] [PubMed]
- Dellit, T.H.; Owens, R.C.; McGowan, J.E., Jr.; Gerding, D.N.; Weinstein, R.A.; Burke, J.P.; Huskins, W.C.; Paterson, D.L.; Fishman, N.O.; Carpenter, C.F.; et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin. Infect. Dis. 2007, 44, 159–177. [Google Scholar] [CrossRef] [PubMed]
- Hersh, A.L.; De Lurgio, S.A.; Thurm, C.; Lee, B.R.; Weissman, S.J.; Courter, J.D.; Brogan, T.V.; Shah, S.S.; Kronman, M.P.; Gerber, J.S.; et al. Antimicrobial Stewardship Programs in Freestanding Children’s Hospitals. Pediatrics 2014, 135, 33–39. [Google Scholar] [CrossRef] [Green Version]
- Tenover, F.C.; Moellering, J.R.C. The Rationale for Revising the Clinical and Laboratory Standards Institute Vancomycin Minimal Inhibitory Concentration Interpretive Criteria for Staphylococcus aureus. Clin. Infect. Dis. 2007, 44, 1208–1215. [Google Scholar] [CrossRef]
- Van Hal, S.J.; Lodise, T.P.; Paterson, D. The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis. Clin. Infect. Dis. 2012, 54, 755–771. [Google Scholar] [CrossRef] [Green Version]
- Frymoyer, A.; Hersh, A.L.; Benet, L.Z.; Guglielmo, J. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr. Infect. Dis. J. 2009, 28, 398–402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Germovsek, E.; Osborne, L.; Gunaratnam, F.; A Lounis, S.; Busquets, F.B.; Standing, J.F.; Sinha, A.K. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data. J. Antimicrob. Chemother. 2019, 74, 1003–1011. [Google Scholar] [CrossRef]
- Burns, P.B.; Rohrich, R.J.; Chung, K.C. The Levels of Evidence and Their Role in Evidence-Based Medicine. Plast. Reconstr. Surg. 2011, 128, 305–310. [Google Scholar] [CrossRef] [Green Version]
- Cataldo, M.A.; Tacconelli, E.; Grilli, E.; Pea, F.; Petrosillo, N. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: Systematic review and meta-analysis. J. Antimicrob. Chemother. 2011, 67, 17–24. [Google Scholar] [CrossRef] [PubMed]
- Hao, J.-J.; Chen, H.; Zhou, J.-X. Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis. Int. J. Antimicrob. Agents 2016, 47, 28–35. [Google Scholar] [CrossRef] [PubMed]
- Costenaro, P.; Minotti, C.; Cuppini, E.; Barbieri, E.; Giaquinto, C.; Donà, D. Optimizing Antibiotic Treatment Strategies for Neonates and Children: Does Implementing Extended or Prolonged Infusion Provide any Advantage? Antibiotics 2020, 9, 329. [Google Scholar] [CrossRef] [PubMed]
Journal Area | Infectious Diseases Papers | Pediatrics Papers | Grand Total |
---|---|---|---|
Grand Total | 68 | 47 | 115 |
IF, Mean (IQR) | 6.5 (4.5–6.4) | 3.9 (2.7–3.9) | 4.6 (IQR 2.9–5.4) |
Time cited, Median (IQR) | 143.5 (244.75–85.75) | 56 (36–83) | 94 (51–178) |
Setting | |||
No-ICU | 64 | 31 | 95 |
ICU setting | 4 | 16 | 20 |
Population | |||
Children | 7 | 20 | 27 |
Children; neonates | 1 | 1 | |
General/adults and children | 56 | 4 | 50 |
Neonates | 4 | 23 | 27 |
Gender of First Authors | |||
Female | 12 | 22 | 34 |
Male | 56 | 25 | 81 |
Gender of Last Authors | |||
Female | 8 | 11 | 19 |
Male | 60 | 36 | 96 |
Topic | Infectious Diseases Papers | Pediatrics Papers | Grand Total | Main Findings | References |
---|---|---|---|---|---|
68 | 47 | 115 | |||
Adverse reactions | 2 | 1 | 3 | Usually mild reactions, good safety profile. Red man syndrome: infusion-related histamine-like reaction; nephrotoxicity and ototoxicity; rash, eosinophilia, thrombophlebitis, chills, fever, neutropenia, and thrombocytopenia. | [6,7,8] |
Healthcare epidemiology | / | 4 | 4 | Vancomycin as first-line therapy for CoNS, Enterococci spp., MRSA and empiric therapy for LOS in NICUs with endemic MRSA; increasing reports of VISA and VRSA. Vancomycin exposure in childhood is associated with IBD development. | [9,10,11,12] |
PK/PD | 2 | 1 | 3 | Time-dependent antibiotic. 25–50% protein-bound, mainly to albumin and immunoglobulins. Almost exclusively eliminated by the renal route via glomerular filtration and to some extent via active tubular secretion. Penetration in biofilm is not optimal. Neonates: Volume of distribution varies between 0.38 and 0.97 L/kg, and clearance varies between 0.63 mL/kg/min (0.038 L/kg/h) and 1.4 mL/kg/min (0.084 L/kg/h). The AUC/MIC value may be the pharmacodynamic parameter that best correlates with a successful outcome. An AUC/MIC ratio ≥400 has been identified as the optimal target for clinical effectiveness. Trough serum vancomycin concentrations for monitoring the effectiveness of vancomycin (renal excretion). The pharmacokinetics of vancomycin in neonates and young infants depends on weight and serum creatinine and showed a wide interindividual variability. Lack of PK studies on continuous infusion. | [1,13,14] |
State of the art | 11 | 2 | 13 | Antibiotic of choice against serious Gram-positive infections, more than 50 years after its introduction. Increasing evidence suggests that it may be losing its clinical efficacy against serious MRSA infections with MICs at the higher end of the susceptibility range. Slowly bactericidal and characterized by suboptimal properties such as PK (requiring twice-daily dosing and serum level monitoring) and complex variable tissue penetration. The optimal dosing in critically ill patients remains a contentious issue. | [15,16,17,18,19,20,21,22,23,24,25,26,27] |
Vancomycin and antibiotic resistance | 25 | 2 | 27 | In 1996 first reported strain of S. aureus with reduced susceptibility to vancomycin. Heteroresistant VRSA: strains of S. aureus that contain vancomycin-resistant subpopulations for which the MICs of vancomycin for the parent strain are 1–4 mg/mL. Vancomycin treatment failures reported with methicillin-resistant S. aureus displaying a MIC of 2 mg/L. Trough serum vancomycin concentrations must be maintained at 110 mg/L to avoid the development of resistance. VRE: several phenotypes, high-level resistance due to altered ligase (vanA and vanB genes on transposon/plasmid). Low-level resistance (MIC 8–32 mg/L) and high-level (MIC ≥ 64 mg/L). Selection pressure, HAI, and hospital outbreaks more frequent. | [28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54] |
Vancomycin and dosing strategies/intermittent vs. continuous | 3 | 8 | 11 | Dosing optimisation is paramount to avoid resistanceand maximise the likelihood of achieving the therapeutic target. Adults: Continuous infusion in critically ill patients, to keep serum concentrations above a targeted MIC and for easier monitoring of drug concentrations and dosage adjustment. Target concentrations are obtained faster, with less variability in daily infused dose, though no difference in efficacy. Decreased risk of adverse reactions, including nephrotoxicity. Neonates, bacterial sepsis: prescription is challenging for high pharmacokinetic variability, lack of consensus on dosing regimen, and therapeutic drug monitoring. Mostly administered in neonates as intermittent infusion. Limited data on continuous infusion, but already used in clinical practice. | [55,56,57,58,59,60,61,62,63,64,65] |
Vancomycin and ototoxicity | 1 | 1 | 2 | Exposure to vancomycin was not associated with failure of automated auditory brainstem response in neonatal hearing screening. No ototoxicity data on continuous infusion in neonates. | [66,67] |
Vancomycin and renal toxicity | 1 | 5 | 6 | Damage due to direct brush border cytotoxic effects. Incidence 11–22%. Not strictly related to specific serum concentrations in children. Elevated trough levels and concomitant furosemide are risk factors. No long-term data on nephrotoxicity in neonates are currently available. | [68,69,70,71,72,73] |
Vancomycin for bloodstream/complicated infections | 15 | 15 | 30 | Antibiotic of choice for MRSA infections for more than 4 decades. Widely used for the treatment of neonatal late-onset sepsis, gram-positive invasive infections in children, catheter-related infections, osteomyelitis, pneumonia, septicemia, soft tissue infections endocarditis, central nervous system infections. | [74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103] |
Vancomycin for C. difficile infection | 5 | 5 | 10 | The incidence of CDI has risen in children since 2000. Most pediatric studies have evaluated the incidence of CDI-related hospitalizations among multicenter cohorts of hospitalized children. Highest rates of asymptomatic colonization with either toxigenic or nontoxigenic strains <12 months of age. Oral vancomycin recommended for treatment of pseudomembranous colitis due to C. difficile, for the first episode (severe/non-severe; first recurrence; second or subsequent recurrence), 10 mg/kg/dose 4 times daily for 10 days. | [104,105,106,107,108,109,110,111,112,113] |
Vancomycin in antibiotic stewardship | 1 | 3 | 4 | Significant decline in vancomycin prescription in hospitalized children with active antibiotic stewardship programs in a multicenter study. Local antibiograms with pathogen-specific susceptibility data should be updated at least annually, to optimize expert-based recommendations for empirical therapy. | [114,115,116,117] |
Vancomycin MIC interpretative criteria | 2 | / | 2 | Over the last 2 decades, isolates with high but susceptible vancomycin MICs have been associated with additional treatment failures and patient mortality in MRSA bloodstream infections. In 2006, the Clinical Laboratory and Standards Institute reduced the vancomycin-susceptible MIC breakpoint for S. aureus from 4 mg/L to 2 mg/L. MIC “creep” as increases over time of central vancomycin MIC tendency. | [118,119] |
Vancomycin in Pediatric Patients-Key Points | |
---|---|
Spectrum of activity | Bactericidal for aerobic and anaerobic gram-positive bacteria, including coagulase-negative Staphylococcus and S.aureus. Bacteriostatic for enterococci. Target: Skin and soft tissue infections, bone, and joint infections, bloodstream infections/sepsis/severe infections in children and neonates, endocarditis, nervous system infections. [1] C.difficile colitis (oral administration) [108] |
Recommended dose—severe infections | Neonates: 10–15 mg/kg (once every 18/12/8 h) [61] |
Children: 60 mg/kg/day in four divided doses [120] | |
Recommended dose—C. difficile colitis | 10 mg/kg/dose four times a day [108] |
Adverse events | Infusion-related: “red man syndrome”; pain at the injection site; allergic reactions. Drug-related toxicity: neutropenia, thrombocytopenia, eosinophilia, thrombophlebitis, chills, fever, rash, nephrotoxicity, and ototoxicity [2,66,70] |
Resistance | VRE: linked to at least 4 genes (Van A-D); selection pressure by extensive use of vancomycin; VISA/VRSA: thickened and aggregated cell walls; S. epidermidis: biofilm [3,4,5,26] |
Gaps of knowledge | PK/PD: AUC/MIC ratio; recommended pharmacodynamic target of AUC 24/MIC >400 [1,120,121] |
Continuous infusion (higher chance of target attainment; safety; limit toxicity) [61,62,65,121] vs intermittent infusion | |
New dosing strategies in neonates; lack of consensus on dosing regimens in neonates with varying gestational and postnatal ages. Need to dose both for clinical efficacy and to reduce the rate of development of resistance. Efficacy (effectiveness) and safety of increased doses of vancomycin and generic formulations [58,61,62,120]. | |
Antibiotic stewardship and avoiding further resistances [117] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Minotti, C.; Barbieri, E.; Giaquinto, C.; Donà, D. Vancomycin Use in Children and Neonates across Three Decades: A Bibliometric Analysis of the Top-Cited Articles. Pathogens 2021, 10, 1343. https://doi.org/10.3390/pathogens10101343
Minotti C, Barbieri E, Giaquinto C, Donà D. Vancomycin Use in Children and Neonates across Three Decades: A Bibliometric Analysis of the Top-Cited Articles. Pathogens. 2021; 10(10):1343. https://doi.org/10.3390/pathogens10101343
Chicago/Turabian StyleMinotti, Chiara, Elisa Barbieri, Carlo Giaquinto, and Daniele Donà. 2021. "Vancomycin Use in Children and Neonates across Three Decades: A Bibliometric Analysis of the Top-Cited Articles" Pathogens 10, no. 10: 1343. https://doi.org/10.3390/pathogens10101343